Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL
H Kantarjian, F Giles, L Wunderle… - … England Journal of …, 2006 - Mass Medical Soc
Background Resistance to imatinib mesylate can occur in chronic myelogenous leukemia
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
H Kantarjian, F Giles, L Wunderle, K Bhalla… - The New England …, 2006 - europepmc.org
Background Resistance to imatinib mesylate can occur in chronic myelogenous leukemia
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
[PDF][PDF] Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
PCP ALL - N Engl J Med, 2006 - researchgate.net
Background Resistance to imatinib mesylate can occur in chronic myelogenous leukemia
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
H Kantarjian, F Giles, L Wunderle… - New England …, 2006 - mdanderson.elsevierpure.com
BACKGROUND: Resistance to imatinib mesylate can occur in chronic myelogenous
leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR …
leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR …
[引用][C] Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
H KANTARJIAN - N Engl J Med., 2006 - cir.nii.ac.jp
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
[PDF][PDF] Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
PCP ALL - N Engl J Med, 2006 - academia.edu
Background Resistance to imatinib mesylate can occur in chronic myelogenous leukemia
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
[PDF][PDF] Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
PCP ALL - N Engl J Med, 2006 - Citeseer
Background Resistance to imatinib mesylate can occur in chronic myelogenous leukemia
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
H Kantarjian, F Giles, L Wunderle… - The New England …, 2006 - pubmed.ncbi.nlm.nih.gov
Background Resistance to imatinib mesylate can occur in chronic myelogenous leukemia
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
H Kantarjian, F Giles, L Wunderle… - New England …, 2006 - scholars.northwestern.edu
BACKGROUND: Resistance to imatinib mesylate can occur in chronic myelogenous
leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR …
leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR …
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
H Kantarjian, F Giles, L Wunderle… - New England …, 2006 - augusta.elsevierpure.com
BACKGROUND: Resistance to imatinib mesylate can occur in chronic myelogenous
leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR …
leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR …